Download
s00414-020-02380-3.pdf 599,65KB
WeightNameValue
1000 Titel
  • Toxicogenetic analysis of Δ9-THC-metabolizing enzymes
1000 Autor/in
  1. Gasse, Angela |
  2. Vennemann, Marielle |
  3. Köhler, Helga |
  4. Schürenkamp, Jennifer |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-07-25
1000 Erschienen in
1000 Quellenangabe
  • 134(6):2095-2103
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00414-020-02380-3 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578149/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • While the impact of genetic polymorphisms on the metabolism of various pharmaceuticals is well known, more data are needed to better understand the specific influence of pharmacogenetics on the metabolism of delta 9-tetrahydocannabinol (Δ9-THC). Therefore, the aim of the study was to analyze the potential impact of variations in genes coding for phase I enzymes of the Δ9-THC metabolism. First, a multiplex assay for genotyping different variants of genes coding for phase I enzymes was developed and applied to 66 Δ9-THC-positive blood samples obtained in cases of driving under the influence of drugs (DUID). Genetic and demographic data as well as plasma concentrations of Δ9-THC, 11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-Δ9-THC), and 11-nor-9-carboxy-Δ9-THC (Δ9-THC-COOH) were combined and statistically investigated. For cytochrome P450 2C19 (CYP2C19) variants, no differences in analyzed cannabinoid concentrations were found. There were also no differences in the concentrations of Δ9-THC and 11-OH-Δ9-THC for the different allelic CPY2C9 status. We recognized significantly lower Δ9-THC-COOH concentrations for CYP2C9*3 (p = 0.001) and a trend of lower Δ9-THC-COOH concentrations for CYP2C9*2 which did not reach statistical significance (p = 0.068). In addition, this study showed significantly higher values in the ratio of Δ9-THC/Δ9-THC-COOH for the carriers of the CYP2C9 variants CYP2C9*2 and CYP2C9*3 compared with the carriers of the corresponding wild-type alleles. Therefore, an impact of variations of the CYP2C9 gene on the interpretation of cannabinoid plasma concentrations in DUID cases should be considered.
1000 Sacherschließung
lokal Original Article
lokal Toxicokinetic
lokal CYP2C9
lokal Cannabis
lokal CYP2C19
lokal Δ9-THC metabolism
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/R2Fzc2UsIEFuZ2VsYQ==|https://frl.publisso.de/adhoc/uri/VmVubmVtYW5uLCBNYXJpZWxsZQ==|https://frl.publisso.de/adhoc/uri/S8O2aGxlciwgSGVsZ2E=|https://orcid.org/0000-0002-7495-7433
1000 Hinweis
  • DeepGreen-ID: 6af7fdfb12d74e6e810ca863e274bebb ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
  1. Toxicogenetic analysis of Δ9-THC-metabolizing enzymes
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6469630.rdf
1000 Erstellt am 2023-11-18T00:19:31.517+0100
1000 Erstellt von 322
1000 beschreibt frl:6469630
1000 Zuletzt bearbeitet 2023-12-01T10:13:31.956+0100
1000 Objekt bearb. Fri Dec 01 10:13:31 CET 2023
1000 Vgl. frl:6469630
1000 Oai Id
  1. oai:frl.publisso.de:frl:6469630 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source